$543.91
-8.15-1.48%
Últ. Act.: Aug 20, 12:56 PM
Vertex Pharmaceuticals Inc
VRTXNASDAQ
Vertex Pharmaceuticals Earnings & Forecasts
Vertex Pharmaceuticals (VRTX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Vertex Pharmaceuticals Guidance
Vertex Pharmaceuticals (VRTX) publicó su última previsión de agosto 3, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $13.1B - $13.2B para el período.
En comparación con la previsión anterior, Vertex Pharmaceuticals mantenido redujo su previsión de ingresos desde un rango anterior de $12.95B - $13.1B.
Vertex Pharmaceuticals ha emitido 16 actualizaciones de orientación entre el octubre 27, 2022 y el agosto 3, 2026. During this period, the company raised its outlook 6 times, reflecting management's growing confidence in business performance.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $4.63 | $4.18 | $4.85 | $4.35 |
| Actual | $4.73 | $4.47 | $5.03 | $4.80 |
| Surprise | +2.16% | +6.94% | +3.71% | +10.3% |
| Revenue | ||||
| Estimate | $3.21B | $2.99B | $3.17B | $3.05B |
| Actual | $3.33B | $2.99B | $3.19B | $3.08B |
| Surprise | +3.74% | -0.24% | +0.54% | +0.80% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $4.80 | $4.78 | $4.64 | $4.88 |
| Revenue | ||||
| Consensus | $3.39B | $3.50B | — | — |